|
EXP002368
|
A cell-penetrating peptide enhances delivery and efficacy of phosphorodiamidate…
|
2022 |
RC-1001 CPP (proprietary)
|
PMO (antisense oligonucleotide)
|
no |
|
|
yes |
yes |
|
EXP002369
|
Blockade of HIF-1α and STAT3 by hyaluronate-conjugated TAT-chitosan-SPION nanop…
|
2021 |
HIV-Tat
|
siRNA
|
yes |
yes |
|
no |
no |
|
EXP002370
|
Blockade of HIF-1α and STAT3 by hyaluronate-conjugated TAT-chitosan-SPION nanop…
|
2021 |
HIV-Tat
|
siRNA
|
yes |
|
|
yes |
yes |
|
EXP002371
|
Antisense peptide nucleic acids against ftsZ and efaA genes inhibit growth and …
|
2020 |
(RXR)4 carrier peptide
|
PNA (antisense oligonucleotide)
|
no |
yes |
|
no |
no |
|
EXP002372
|
A non-covalent strategy combining cationic lipids and CPPs to enhance delivery …
|
2010 |
S413-PV
|
SSO (2′-O-methyl oligoribonucleotide)
|
yes |
yes |
|
no |
no |
|
EXP002373
|
A non-covalent strategy combining cationic lipids and CPPs to enhance delivery …
|
2010 |
Reverse NLS
|
SSO (2′-O-methyl oligoribonucleotide)
|
yes |
yes |
|
no |
no |
|
EXP002374
|
A non-covalent strategy combining cationic lipids and CPPs to enhance delivery …
|
2010 |
Scrambled S413-PV
|
SSO (2′-O-methyl oligoribonucleotide)
|
yes |
yes |
|
no |
no |
|
EXP002375
|
A non-covalent strategy combining cationic lipids and CPPs to enhance delivery …
|
2010 |
Tat
|
SSO (2′-O-methyl oligoribonucleotide)
|
yes |
yes |
|
no |
no |
|
EXP002376
|
In Vivo Delivery of siRNAs Targeting EGFR and BRD4 Expression by Peptide-Modifi…
|
2021 |
GALA
|
siRNA
|
yes |
yes |
yes |
no |
no |
|
EXP002377
|
In Vivo Delivery of siRNAs Targeting EGFR and BRD4 Expression by Peptide-Modifi…
|
2021 |
GALA
|
siRNA
|
yes |
|
yes |
yes |
yes |
|
EXP002378
|
In Vivo Delivery of siRNAs Targeting EGFR and BRD4 Expression by Peptide-Modifi…
|
2021 |
CREKA
|
siRNA
|
yes |
yes |
|
no |
no |
|
EXP002379
|
In Vivo Delivery of siRNAs Targeting EGFR and BRD4 Expression by Peptide-Modifi…
|
2021 |
CREKA
|
siRNA
|
yes |
|
|
yes |
yes |
|
EXP002380
|
Targeting Listeria monocytogenes rpoA and rpoD genes using peptide nucleic acids
|
2013 |
anti-rpoA (KFF)3K-PNA
|
PNA (antisense oligonucleotide)
|
no |
yes |
|
no |
no |
|
EXP002381
|
Targeting Listeria monocytogenes rpoA and rpoD genes using peptide nucleic acids
|
2013 |
anti-rpoA (KFF)3K-PNA
|
PNA (antisense oligonucleotide)
|
no |
|
|
yes |
yes |
|
EXP002382
|
Targeting Listeria monocytogenes rpoA and rpoD genes using peptide nucleic acids
|
2013 |
anti-rpoD (KFF)3K-PNA
|
PNA (antisense oligonucleotide)
|
no |
yes |
|
no |
no |
|
EXP002383
|
Targeting Listeria monocytogenes rpoA and rpoD genes using peptide nucleic acids
|
2013 |
anti-rpoD (KFF)3K-PNA
|
PNA (antisense oligonucleotide)
|
no |
|
|
yes |
no |
|
EXP002384
|
Targeting Listeria monocytogenes rpoA and rpoD genes using peptide nucleic acids
|
2013 |
control (KFF)3K-PNA
|
PNA (antisense oligonucleotide)
|
no |
yes |
|
no |
no |
|
EXP002385
|
Bacterial outer membrane vesicle nanorobot
|
2024 |
CPP (ClyA-CPP fusion)
|
siRNA
|
yes |
yes |
|
no |
no |
|
EXP002386
|
Bacterial outer membrane vesicle nanorobot
|
2024 |
CPP (ClyA-CPP fusion)
|
siRNA
|
yes |
|
|
yes |
yes |
|
EXP002387
|
Bioengineered Extracellular Membranous Nanovesicles for Efficient Small-Interfe…
|
2016 |
RGD
|
siRNA
|
yes |
yes |
|
no |
no |
|
EXP002388
|
Bioengineered Extracellular Membranous Nanovesicles for Efficient Small-Interfe…
|
2016 |
RGD
|
siRNA
|
yes |
|
|
yes |
yes |
|
EXP002389
|
Transportan-derived cell-penetrating peptide delivers siRNA to inhibit replicat…
|
2019 |
T9(dR)
|
siRNA
|
yes |
yes |
|
no |
no |
|
EXP002390
|
Transportan-derived cell-penetrating peptide delivers siRNA to inhibit replicat…
|
2019 |
T9(dR)
|
siRNA
|
no |
|
|
yes |
yes |
|
EXP002391
|
Immobilization of HIV‐1 TAT peptide on gold nanoparticles: A feasible approach …
|
2020 |
HIV-1 TAT CPP
|
siRNA
|
yes |
yes |
|
no |
no |
|
EXP002392
|
Protein and siRNA delivery by transportan and transportan 10 into colorectal ca…
|
2014 |
TP
|
siRNA
|
yes |
yes |
|
no |
no |
|
EXP002393
|
Protein and siRNA delivery by transportan and transportan 10 into colorectal ca…
|
2014 |
TP-biot1
|
siRNA
|
yes |
yes |
|
no |
no |
|
EXP002394
|
Protein and siRNA delivery by transportan and transportan 10 into colorectal ca…
|
2014 |
TP-biot13
|
siRNA
|
yes |
yes |
|
no |
no |
|
EXP002395
|
Protein and siRNA delivery by transportan and transportan 10 into colorectal ca…
|
2014 |
TP10
|
siRNA
|
yes |
yes |
|
no |
no |
|
EXP002396
|
Protein and siRNA delivery by transportan and transportan 10 into colorectal ca…
|
2014 |
TP10-biot1
|
siRNA
|
yes |
yes |
|
no |
no |
|
EXP002397
|
Enzyme-sensitive nanoparticles, smart TAT and cetuximab conjugated immunoliposo…
|
2022 |
TAT
|
siRNA
|
yes |
yes |
|
no |
no |
|
EXP002398
|
Enzyme-sensitive nanoparticles, smart TAT and cetuximab conjugated immunoliposo…
|
2022 |
MMP2 substrate
|
siRNA
|
yes |
yes |
|
no |
no |
|
EXP002399
|
Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino…
|
2021 |
(RXR)4 CPP
|
PMO (antisense morpholino oligomer)
|
no |
no |
|
no |
no |
|
EXP002400
|
Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino…
|
2021 |
(RXR)4 CPP
|
PMO (antisense morpholino oligomer)
|
no |
yes |
|
no |
no |
|
EXP002401
|
Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino…
|
2021 |
(RXR)4 CPP
|
PMO (antisense morpholino oligomer)
|
no |
yes |
|
no |
no |
|
EXP002402
|
Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino…
|
2021 |
(RXR)4 CPP
|
PMO (antisense morpholino oligomer)
|
no |
yes |
|
no |
no |
|
EXP002403
|
Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino…
|
2021 |
(RXR)4 CPP
|
PMO (antisense morpholino oligomer)
|
no |
yes |
|
no |
no |
|
EXP002404
|
Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino…
|
2021 |
(RXR)4 CPP
|
PMO (antisense morpholino oligomer)
|
no |
yes |
|
no |
no |
|
EXP002405
|
Treatment of Melanoma by Nano-conjugate-Delivered Wee1 siRNA
|
2021 |
R8–cRGD CPP
|
siRNA
|
yes |
yes |
|
no |
no |
|
EXP002406
|
Treatment of Melanoma by Nano-conjugate-Delivered Wee1 siRNA
|
2021 |
R8–cRGD CPP
|
siRNA
|
no |
|
|
yes |
yes |
|
EXP002407
|
Nanogels Enable Efficient miRNA Delivery and Target Gene Downregulation in Tran…
|
2019 |
HIV-1 TAT
|
miRNA
|
yes |
yes |
|
no |
no |
|
EXP002408
|
Nanogels Enable Efficient miRNA Delivery and Target Gene Downregulation in Tran…
|
2019 |
HIV-1 TAT
|
miRNA
|
yes |
yes |
|
no |
no |
|
EXP002409
|
Nanogels Enable Efficient miRNA Delivery and Target Gene Downregulation in Tran…
|
2019 |
HIV-1 TAT
|
miRNA
|
yes |
yes |
|
no |
no |
|
EXP002410
|
Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas
|
2017 |
myristoyl-TP-iRGD
|
siRNA
|
yes |
yes |
|
no |
no |
|
EXP002411
|
Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas
|
2017 |
myristoyl-TP-iRGE (scrambled control)
|
siRNA
|
yes |
no |
|
no |
no |
|
EXP002412
|
Co-Polymer Carrier with Dual Advantages of Cartilage-Penetrating and Targeting …
|
2022 |
CAP (cartilage-targeting peptide)
|
miRNA
|
yes |
yes |
yes |
no |
no |
|
EXP002413
|
Co-Polymer Carrier with Dual Advantages of Cartilage-Penetrating and Targeting …
|
2022 |
CAP (cartilage-targeting peptide)
|
miRNA
|
no |
|
|
yes |
yes |
|
EXP002414
|
Modularized Gold Nanocarriers for TAT-Mediated Delivery of siRNA
|
2016 |
TAT
|
siRNA
|
yes |
yes |
yes |
no |
no |
|
EXP002415
|
The promoted delivery of RRM2 siRNA to vascular smooth muscle cells through lip…
|
2018 |
CyLoP-1 (CCPs)
|
siRNA
|
yes |
yes |
|
no |
no |
|
EXP002418
|
A cell-penetrating phospholamban-specific RNA aptamer enhances Ca2+ transients …
|
2014 |
modified TAT (mTAT)
|
RNA aptamer
|
yes |
yes |
|
no |
no |
|
EXP002419
|
Effect of HIV-1 TAT Peptide Fusion on 5′ mRNA Cap Analogs Cell Membrane Permeab…
|
2020 |
HIV-1 TAT
|
cap analog (nucleotide)
|
yes |
yes |
|
no |
no |
|
EXP002420
|
Effect of HIV-1 TAT Peptide Fusion on 5′ mRNA Cap Analogs Cell Membrane Permeab…
|
2020 |
HIV-1 TAT
|
cap analog (dinucleotide)
|
yes |
yes |
|
no |
no |
|
EXP002421
|
Synthesis and Studies on Cell-Penetrating Peptides
|
2009 |
Peptide 1
|
antisense oligonucleotide (AS-ODN)
|
yes |
yes |
|
no |
no |
|
EXP002422
|
Synthesis and Studies on Cell-Penetrating Peptides
|
2009 |
Peptide 1a
|
antisense oligonucleotide (AS-ODN)
|
yes |
yes |
|
no |
no |
|
EXP002423
|
Synthesis and Studies on Cell-Penetrating Peptides
|
2009 |
Peptide 2
|
antisense oligonucleotide (AS-ODN)
|
yes |
no |
|
no |
no |
|
EXP002424
|
Synthesis and Studies on Cell-Penetrating Peptides
|
2009 |
Peptide 2a
|
antisense oligonucleotide (AS-ODN)
|
yes |
no |
|
no |
no |
|
EXP002425
|
Synthesis and Studies on Cell-Penetrating Peptides
|
2009 |
Peptide 3
|
antisense oligonucleotide (AS-ODN)
|
yes |
no |
|
no |
no |
|
EXP002426
|
Synthesis and Studies on Cell-Penetrating Peptides
|
2009 |
Peptide 3a
|
antisense oligonucleotide (AS-ODN)
|
yes |
no |
|
no |
no |
|
EXP002427
|
Synthesis and Studies on Cell-Penetrating Peptides
|
2009 |
Peptide 4
|
antisense oligonucleotide (AS-ODN)
|
yes |
no |
|
no |
no |
|
EXP002428
|
Synthesis and Studies on Cell-Penetrating Peptides
|
2009 |
Peptide 4a
|
antisense oligonucleotide (AS-ODN)
|
yes |
no |
|
no |
no |
|
EXP002429
|
Synthesis and Studies on Cell-Penetrating Peptides
|
2009 |
Peptide 5
|
antisense oligonucleotide (AS-ODN)
|
yes |
no |
|
no |
no |
|
EXP002430
|
Synthesis and Studies on Cell-Penetrating Peptides
|
2009 |
Peptide 5a
|
antisense oligonucleotide (AS-ODN)
|
yes |
no |
|
no |
no |
|
EXP002431
|
Synthesis and Studies on Cell-Penetrating Peptides
|
2009 |
Peptide 6
|
antisense oligonucleotide (AS-ODN)
|
yes |
no |
|
no |
no |
|
EXP002432
|
Synthesis and Studies on Cell-Penetrating Peptides
|
2009 |
Peptide 6a
|
antisense oligonucleotide (AS-ODN)
|
yes |
no |
|
no |
no |
|
EXP002433
|
Targeting Cytokine Expression in Glial Cells by Cellular Delivery of an NF-κB D…
|
2007 |
Transportan-10 (TP10)
|
DNA decoy oligonucleotide
|
yes |
yes |
|
no |
no |
|
EXP002434
|
Targeting Cytokine Expression in Glial Cells by Cellular Delivery of an NF-κB D…
|
2007 |
Cys-PNA 9-mer
|
DNA decoy oligonucleotide
|
no |
no |
|
no |
no |
|
EXP002435
|
DG9-conjugated morpholino rescues phenotype in SMA mice by reaching the CNS via…
|
2023 |
DG9
|
PMO (splice-switching antisense morpholino)
|
yes |
|
|
yes |
yes |
|
EXP002436
|
DG9-conjugated morpholino rescues phenotype in SMA mice by reaching the CNS via…
|
2023 |
DG9
|
PMO (splice-switching antisense morpholino)
|
yes |
|
|
yes |
yes |
|
EXP002437
|
DG9-conjugated morpholino rescues phenotype in SMA mice by reaching the CNS via…
|
2023 |
R6G
|
PMO (splice-switching antisense morpholino)
|
no |
|
|
yes |
yes |
|
EXP002438
|
Delivery of siRNA Using Functionalized Gold Nanorods Enhances Anti-Osteosarcoma…
|
2021 |
CPP-Pep-TH
|
siRNA
|
yes |
yes |
yes |
no |
no |
|
EXP002439
|
Delivery of siRNA Using Functionalized Gold Nanorods Enhances Anti-Osteosarcoma…
|
2021 |
CPP-Pep-TH
|
siRNA
|
yes |
|
yes |
yes |
yes |
|
EXP002440
|
RNase non-sensitive and endocytosis independent siRNA delivery system
|
2013 |
CPP-SWCNT
|
siRNA
|
yes |
yes |
yes |
no |
no |
|
EXP002441
|
Protein Expression Correlates Linearly with mRNA Dose over Up to Five Orders of…
|
2021 |
Pepfect14
|
mRNA
|
yes |
yes |
no |
no |
no |
|
EXP002442
|
Multifunctional elastin-like polypeptide nanocarriers for efficient miRNA deliv…
|
2024 |
Tat-A86
|
miRNA
|
yes |
yes |
yes |
no |
no |
|
EXP002443
|
Multifunctional elastin-like polypeptide nanocarriers for efficient miRNA deliv…
|
2024 |
Tat-A86
|
miRNA
|
yes |
|
yes |
yes |
yes |
|
EXP002444
|
Development of non-viral vectors for neuronal-targeted delivery of CRISPR-Cas9 …
|
2022 |
C2-PepFect14
|
CRISPR-Cas9 RNP
|
yes |
yes |
|
no |
no |
|
EXP002445
|
In Vivo Follow-Up of Gene Inhibition in Solid Tumors Using Peptide-Based Nanopa…
|
2021 |
WRAP5
|
siRNA
|
yes |
yes |
|
no |
no |
|
EXP002446
|
In Vivo Follow-Up of Gene Inhibition in Solid Tumors Using Peptide-Based Nanopa…
|
2021 |
WRAP5
|
siRNA
|
yes |
|
|
yes |
yes |
|
EXP002447
|
Chemical conjugation of an mRNA cap analogue with a cell-penetrating peptide as…
|
2014 |
MPS
|
mRNA cap analogue
|
no |
yes |
|
no |
no |
|
EXP002448
|
Immortalized Canine Dystrophic Myoblast Cell Lines for Development of Peptide-C…
|
2021 |
Pip8b2
|
SSO (PMO)
|
yes |
yes |
yes |
no |
no |
|
EXP002449
|
EGFP-Based Protein Nanoparticles with Cell-Penetrating Peptide for Efficient si…
|
2015 |
H6-TatEGFP
|
siRNA
|
yes |
yes |
yes |
no |
no |
|
EXP002450
|
Carrier PNA for shRNA delivery into cells
|
2009 |
Carrier-PNA-R8
|
shRNA
|
yes |
yes |
no |
no |
no |
|
EXP002451
|
Role of nuclear localization signals in the DNA delivery function of Chikunguny…
|
2021 |
NLS1
|
plasmid DNA
|
yes |
yes |
|
no |
no |
|
EXP002452
|
Role of nuclear localization signals in the DNA delivery function of Chikunguny…
|
2021 |
NLS2
|
plasmid DNA
|
no |
no |
|
no |
no |
|
EXP002453
|
Macrophage membrane-reversibly camouflaged nanotherapeutics accelerate fracture…
|
2024 |
PG (α-helical polypeptide)
|
siRNA
|
yes |
yes |
yes |
no |
no |
|
EXP002454
|
Macrophage membrane-reversibly camouflaged nanotherapeutics accelerate fracture…
|
2024 |
PG (α-helical polypeptide)
|
siRNA
|
yes |
|
yes |
yes |
yes |
|
EXP002455
|
Tumor Cell Lysate-Based Multifunctional Nanoparticles Facilitate Enhanced mRNA …
|
2024 |
TAT-iRGD
|
mRNA
|
yes |
yes |
|
no |
no |
|
EXP002456
|
Tumor Cell Lysate-Based Multifunctional Nanoparticles Facilitate Enhanced mRNA …
|
2024 |
TAT-iRGD
|
mRNA
|
yes |
|
|
yes |
yes |
|
EXP002457
|
TAT decorated siRNA polyplexes for inhalation delivery in anti-asthma therapy
|
2023 |
HIV-1 TAT(47–57)
|
siRNA
|
yes |
yes |
|
no |
no |
|
EXP002458
|
Novel peptide (RATH) mediated delivery of peptide nucleic acids for antiviral i…
|
2021 |
RATH
|
PNA
|
yes |
yes |
|
no |
no |
|
EXP002459
|
Novel peptide (RATH) mediated delivery of peptide nucleic acids for antiviral i…
|
2021 |
RATH-1
|
PNA
|
yes |
yes |
|
no |
no |
|
EXP002460
|
Novel peptide (RATH) mediated delivery of peptide nucleic acids for antiviral i…
|
2021 |
RATH-2
|
PNA
|
yes |
yes |
|
no |
no |
|
EXP002461
|
Neoantigen-specific mRNA/DC vaccines for effective anticancer immunotherapy
|
2024 |
RALA
|
mRNA
|
yes |
yes |
|
no |
no |
|
EXP002462
|
Neoantigen-specific mRNA/DC vaccines for effective anticancer immunotherapy
|
2024 |
RALA
|
mRNA
|
no |
|
|
yes |
yes |
|
EXP002463
|
Neoantigen-specific mRNA/DC vaccines for effective anticancer immunotherapy
|
2024 |
RALA
|
mRNA
|
no |
|
|
yes |
no |
|
EXP002464
|
Intraocular siRNA Delivery Mediated by Penetratin Derivative to Silence Orthoto…
|
2023 |
89WP (penetratin derivative)
|
siRNA
|
yes |
yes |
|
no |
no |
|
EXP002465
|
Intraocular siRNA Delivery Mediated by Penetratin Derivative to Silence Orthoto…
|
2023 |
89WP (penetratin derivative)
|
siRNA
|
yes |
|
|
yes |
yes |
|
EXP002466
|
Comparison of Physicochemical Properties of LipoParticles as mRNA Carrier Prepa…
|
2022 |
LAH4-L1
|
mRNA
|
no |
yes |
|
no |
no |
|
EXP002467
|
Comparison of Physicochemical Properties of LipoParticles as mRNA Carrier Prepa…
|
2022 |
LAH4-L1
|
mRNA
|
no |
yes |
|
no |
no |
|
EXP002468
|
Higher Order Architecture of Designer Peptides Forms Bioinspired 10 nm siRNA De…
|
2019 |
V1
|
siRNA
|
yes |
yes |
|
no |
no |
|
EXP002469
|
Higher Order Architecture of Designer Peptides Forms Bioinspired 10 nm siRNA De…
|
2019 |
V2
|
siRNA
|
yes |
yes |
|
no |
no |